Drug
U3 1402
U3 1402: highest development phase Phase 1, developed by Daiichi Sankyo. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Daiichi Sankyo
Trials
| Drug | Phase | Indication |
|---|---|---|
| U3 1402 NCT04610528 | Phase 1 | Breast Cancer |
Latest
No recent events.
Follow U3 1402 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.